Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment
about
Mechanisms of acupuncture-electroacupuncture on persistent painAntagonist treatment of opioid withdrawal translational low dose approachNaloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphineTolerance and withdrawal from prolonged opioid use in critically ill children.High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence.Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.How to design an opioid drug that causes reduced tolerance and dependence.Abnormal nociception and opiate sensitivity of STOP null mice exhibiting elevated levels of the endogenous alkaloid morphinePilot study of continuous co-infusion of morphine and naloxone in children with sickle cell pain crisisFunctional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.Agonist-antagonist combinations in opioid dependence: a translational approachAugmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegenerationThe role of proopiomelanocortin (POMC) in sequentially dependent self-injurious behavior.Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study.The analgesic potential of cannabinoids.Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal.Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrainHydrogen sulfide attenuates opioid dependence by suppression of adenylate cyclase/cAMP pathway.Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.Intrathecal drug administration in chronic pain syndromes.Glial dysfunction and persistent neuropathic postsurgical pain.Extremely low frequency magnetic fields can either increase or decrease analgaesia in the land snail depending on field and light conditions.Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence.Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide.Opioid tolerance in neonates: a state-of-the-art review.Low doses of alpha 2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance.A randomized clinical trial of the effects of ultra-low-dose naloxone infusion on postoperative opioid requirements and recovery.The stereoisomer (+)-naloxone potentiates G-protein coupling and feeding associated with stimulation of mu opioid receptors in the parabrachial nucleus.Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats.Ultra-Low Doses of Naltrexone Enhance the Antiallodynic Effect of Pregabalin or Gabapentin in Neuropathic Rats.Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.
P2860
Q26866252-314C4E6D-6296-4283-8820-E2CB262B30CAQ28247052-4ABA9B76-EAA8-403B-AEC1-502347A12E16Q28573276-5FA37506-A462-4564-A818-EBF45C4BB207Q30428413-34E948D1-1FEF-46A5-B4A2-E633B9E1C801Q33318465-5DE64DE9-B1BD-41C1-AA75-96FBC42A6F70Q33793250-63170760-32B5-49D0-A6E2-BBD1C3F8C8F0Q33884718-17B487C9-0362-445F-9149-691E8DD59F71Q34144947-F24D5A72-DA29-4E3D-A572-1CA1518FE593Q34471271-59272621-B6E6-4963-B723-AA32FB94C3D0Q34582590-5A01593A-950C-4DAA-B8F3-6F03409E0C15Q35264421-4F9FDDF6-F2AC-46AB-8E18-0ABC8AF7D599Q35327954-6B7B94A2-FE68-48C1-AD4F-F05542D88D6EQ35848930-807E5BEE-48A0-49B7-BCEA-DC58249022D0Q36053125-F8FD0F32-6FD3-4C75-8C39-EE2361C51DBCQ36474012-474D149A-5F00-4C78-93D9-ABD1A8B2BEFFQ36958963-594B2920-5F2C-4D2D-9FEB-56F9AD77CF0FQ36973386-96A88750-8DD5-4075-93E8-97BA69BB2F10Q37057325-2E5695D3-A778-41FB-89EA-2CFBDCA8CAD2Q37102172-623F833A-3216-4838-B964-998CBF6DF034Q37240000-9741814B-F49D-4350-9C7E-BCF17DFF66E3Q37433909-76B33E2C-D745-4C83-9967-BA98BB2C8F6EQ38097075-7DDB8DDA-47E9-4422-8166-93BE0F656957Q38151939-BBFBFF0F-9D6A-4B3A-B694-DA8DBF566727Q39210606-0DC602EC-65C0-4B5E-ACEB-D3919DE56566Q40766422-3FE7C512-8FDC-48F6-93A1-5966869ABCE3Q41247864-C32042C4-198C-464C-ABD5-77852A60B87FQ41605692-C54E5824-6216-411C-AB17-171B1B179DFFQ43069472-33EF4972-A1A0-44F3-83D3-B730537B0FE6Q43223809-2D155885-ADED-4412-89AA-7AA268283F2DQ44329973-D3083789-A7B2-40B0-B9CC-15534DC19D1BQ44337706-AC95C317-FDAE-410F-A36D-0D6098CB2BE4Q46793642-79C35B15-0A1F-4897-AFC9-9F57E5D87FBDQ48134405-177415FF-C440-49E3-BA9A-9656341F274AQ49074804-8B7B19A1-00F3-4C45-9E7C-4A76DD17BCFB
P2860
Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment
description
1995 nî lūn-bûn
@nan
1995 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Ultra-low concentrations of na ...... nce during chronic cotreatment
@ast
Ultra-low concentrations of na ...... nce during chronic cotreatment
@en
type
label
Ultra-low concentrations of na ...... nce during chronic cotreatment
@ast
Ultra-low concentrations of na ...... nce during chronic cotreatment
@en
prefLabel
Ultra-low concentrations of na ...... nce during chronic cotreatment
@ast
Ultra-low concentrations of na ...... nce during chronic cotreatment
@en
P2860
P356
P1476
Ultra-low concentrations of na ...... nce during chronic cotreatment
@en
P2093
P2860
P304
10540-10544
P356
10.1073/PNAS.92.23.10540
P407
P577
1995-11-01T00:00:00Z